biote (BTMD) AI Stock Analysis

• Market Cap: $141.89M
• Dividend Yield: N/A
• Average Volume (3M): 107.28K
• Price to Earnings (P/E): 3.2
• Beta (1Y): 0.96
• Revenue Growth: 6.32%
• EPS Growth: 344.42%
• Country: US
• Employees: 217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.10
• Shares Outstanding: 33,280,228
• 10 Day Avg. Volume: 121,902
• 30 Day Avg. Volume: 107,275
• PEG Ratio: -2.30
• Price to Book (P/B): -2.00
• Price to Sales (P/S): 1.07
• P/FCF Ratio: 5.46
• Enterprise Value/Market Cap: 1.89
• Enterprise Value/Revenue: 1.35
• Enterprise Value/Gross Profit: 1.87
• Enterprise Value/Ebitda: 4.76
• 1Y Price Target: $4.88
• Price Target Upside: 70.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 52 Neutral
• Price Target: $3.00 ▲(4.53% Upside)

Biote's overall stock score reflects significant financial challenges, with declining revenue and high leverage posing risks. While the stock appears undervalued, technical indicators are neutral, and strategic initiatives from the earnings call are yet to yield results. The focus on dietary supplements offers a growth avenue, but execution risks remain.

Positive Factors

Gross Profit Margin

The improvement in gross profit margin indicates effective cost management and operational efficiency, which can enhance profitability over the long term.

Dietary Supplement Growth

Strong growth in dietary supplements, especially via e-commerce, suggests a successful diversification strategy and potential for future revenue expansion.

Adjusted EBITDA Increase

The rise in adjusted EBITDA reflects improved operational performance and cost control, which can support financial stability and growth.

Negative Factors

Declining Procedure Revenue

The decline in procedure revenue due to slower clinic growth and higher attrition poses a risk to sustained revenue streams and market position.

Negative Stockholders' Equity

Negative equity indicates financial instability, limiting the company's ability to raise capital and invest in growth opportunities.

Cash Flow Challenges

Declining free cash flow suggests liquidity constraints, which could hinder the company's ability to fund operations and strategic initiatives.

biote Business Overview & Revenue Model

Company Description

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

How the Company Makes Money

Biote generates revenue primarily through the sale of its hormone replacement therapy products and services. The company's revenue model is built on a subscription basis for healthcare providers who utilize Biote's training, support, and products in their practice. Key revenue streams include the direct sale of hormone therapy products, service fees for training healthcare professionals, and ongoing support services. Additionally, Biote may benefit from partnerships with healthcare providers and clinics, which can enhance its market reach and customer base, further contributing to its earnings.

biote Financial Statement Overview

Summary

The company shows strong revenue growth and profitability improvements, with a healthy gross profit margin of 71.2% TTM and a net profit margin of 10.9% TTM. However, the balance sheet is concerning due to negative equity, indicating liabilities exceed assets, which poses a financial risk. Cash flow is robust, with strong free cash flow generation, but negative investing cash flow could impact future growth.

Income Statement

The company shows a positive trend in revenue growth, with a notable increase in total revenue from previous years. Gross profit margin is healthy at approximately 71.2% TTM. Net profit margin has improved significantly to 10.9% TTM from lower levels in previous years, indicating better cost management and operational efficiency. However, EBIT and EBITDA margins are moderate at 15.5% and 9.1% TTM, respectively, suggesting room for improvement in operational leverage.

Balance Sheet

The balance sheet is concerning with a negative stockholders' equity indicating that liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, highlighting financial risk. Despite these challenges, the company has managed to increase its cash reserves, which could provide some liquidity buffer. The equity ratio remains negative due to the negative equity, reflecting a need for stronger financial restructuring.

Cash Flow

Cash flow generation is strong, with positive free cash flow and operating cash flow. The free cash flow to net income ratio indicates efficient conversion of earnings into cash. The company improved its operating cash flow to net income ratio, suggesting effective cash management. The free cash flow growth rate is substantial, reflecting improved cash generation capabilities. However, investing cash flow remains negative, which could impact future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.07M	197.19M	185.36M	164.96M	139.40M	116.57M
Gross Profit	143.11M	139.06M	127.48M	110.38M	90.58M	71.64M
EBITDA	56.24M	15.59M	9.23M	9.24M	35.98M	32.91M
Net Income	31.31M	3.16M	3.32M	1.32M	32.62M	29.16M
Balance Sheet
Total Assets	104.80M	122.37M	155.29M	111.64M	54.33M	32.59M
Cash, Cash Equivalents and Short-Term Investments	19.60M	39.34M	89.00M	79.23M	26.77M	17.21M
Total Debt	107.89M	110.86M	114.87M	120.43M	37.34M	42.35M
Total Liabilities	183.64M	224.57M	191.84M	169.92M	50.20M	49.66M
Stockholders Equity	-78.84M	-105.93M	-29.40M	-44.46M	4.13M	-17.07M
Cash Flow
Free Cash Flow	34.98M	38.81M	24.17M	-10.99M	29.91M	25.03M
Operating Cash Flow	41.48M	45.24M	26.88M	-9.16M	33.72M	26.43M
Investing Cash Flow	-7.09M	-18.80M	-2.71M	-1.84M	-3.81M	-1.39M
Financing Cash Flow	-41.19M	-76.08M	-14.38M	63.46M	-20.34M	-18.32M

biote Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTMD, the sentiment is Negative. The current price of 2.87 is below the 20-day moving average (MA) of 2.88, below the 50-day MA of 3.10, and below the 200-day MA of 3.79, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 46.57 is Neutral, neither overbought nor oversold. The STOCH value of 20.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTMD.

biote Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BTMD	―	$141.89M	3.18	―	―	6.32%	344.42%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DCGO	―	$106.61M	―	-5.98%	―	-41.31%	-163.08%
PIII	―	$63.54M	-0.18	-138.17%	―	4.20%	-54.16%
JYNT	―	$121.06M	―	-16.16%	―	-40.65%	85.56%
CCM	―	$23.71M	-1.05	―	―	-22.38%	56.66%
CCEL	―	$35.04M	-73.48	―	8.87%	-0.29%	94.56%

biote Corporate Events

Biote Corp. Earnings Call: Growth Amid Challenges

During Biote Corp.’s recent earnings call, the sentiment was a mix of optimism and caution. The company reported solid growth in its dietary supplements segment and improvements in gross profit margins and adjusted EBITDA. However, these positive developments were tempered by flat overall revenue, a decline in procedure revenue, and significant disruptions due to organizational changes. Additionally, there was a notable decrease in cash reserves. Biote is currently navigating a transition phase with strategic initiatives aimed at fostering long-term growth, though current challenges have impacted its performance.

Biote Corp. Reports Strong Q2 2025 Financial Results

Biote Corp., a prominent player in preventive healthcare, specializes in personalized hormone optimization and therapeutic wellness solutions, primarily serving the healthcare sector with innovative approaches to healthy aging. In its latest earnings report for the second quarter of 2025, Biote Corp. highlighted a strong performance driven by increased sales in dietary supplements and an expansion in gross profit margins, despite a slight decrease in overall revenue compared to the previous year. The company also announced a strategic corporate reorganization aimed at fostering growth and enhancing value creation.